Mavacamten
Pre-clinicalRecruiting 0 watching 0 views this week๐ค Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Hypertrophic Cardiomyopathy
Conditions
Obstructive Hypertrophic Cardiomyopathy
Trial Timeline
May 10, 2024 โ Jun 30, 2027
NCT ID
NCT06551129About Mavacamten
Mavacamten is a pre-clinical stage product being developed by Bristol Myers Squibb for Obstructive Hypertrophic Cardiomyopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06551129. Target conditions include Obstructive Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07361289 | Pre-clinical | Recruiting |
| NCT07004972 | Approved | Recruiting |
| NCT07383025 | Pre-clinical | Recruiting |
| NCT06146660 | Pre-clinical | Recruiting |
| NCT06338202 | Pre-clinical | Completed |
| NCT06551129 | Pre-clinical | Recruiting |
| NCT06549608 | Pre-clinical | Active |
| NCT06112743 | Approved | Active |
| NCT07107373 | Pre-clinical | Active |
| NCT05939700 | Pre-clinical | Recruiting |
| NCT06023186 | Pre-clinical | Recruiting |
| NCT07168655 | Pre-clinical | Completed |
| NCT05719805 | Phase 1 | Completed |
| NCT05582395 | Phase 3 | Completed |
| NCT05414175 | Phase 3 | Completed |
| NCT05362045 | Phase 1 | Completed |
| NCT04766892 | Phase 2 | Completed |
| NCT03723655 | Phase 2/3 | Completed |
| NCT03496168 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Hypertrophic Cardiomyopathy